Sanofi (SNY) Shares Sold by Eaton Vance Management
Eaton Vance Management decreased its position in shares of Sanofi (NYSE:SNY) by 4.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,716 shares of the company’s stock after selling 4,045 shares during the period. Eaton Vance Management’s holdings in Sanofi were worth $3,771,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Fisher Asset Management LLC increased its position in Sanofi by 8.1% during the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares during the period. Global Financial Private Capital LLC acquired a new position in Sanofi during the first quarter worth approximately $35,034,000. Bank of America Corp DE increased its position in Sanofi by 8.2% during the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in Sanofi during the first quarter worth approximately $7,619,000. Finally, Lockheed Martin Investment Management Co. acquired a new position in Sanofi during the first quarter worth approximately $6,303,000. 9.33% of the stock is currently owned by institutional investors.
SNY has been the topic of several research analyst reports. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Friday, June 2nd. Argus reissued a “buy” rating and issued a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Cowen and Company reissued a “market perform” rating and issued a $52.00 target price (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $54.00.
In related news, major shareholder Sanofi purchased 105,820 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.
Sanofi (NYSE:SNY) opened at 48.43 on Friday. The stock has a 50 day moving average price of $48.30 and a 200-day moving average price of $47.32. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24. The firm has a market cap of $121.63 billion, a price-to-earnings ratio of 11.54 and a beta of 0.88.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.74. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts forecast that Sanofi will post $3.34 earnings per share for the current year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.